Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis

Abrocitinib, a JAK1 inhibitor approved for atopic dermatitis, is being explored for off-label uses in various dermatological conditions. A review of 37 papers involving 103 patients highlighted its application in vitiligo, prurigo nodularis, and hand eczema, each with 12 cases, as well as lichen sclerosus and chronic pruritus with 10 cases each. Other conditions like pityriasis rubra pilaris and alopecia areata had 5 cases each, while erythematotelangiectatic rosacea and steroid-induced rosacea had 4 cases each. Most studies reported favorable outcomes, except for one case of erythematotelangiectatic rosacea, indicating Abrocitinib's potential beyond its primary indication.